novo nordisk weight loss - Search News

Novo Rises

Novo Nordisk next-gen shot shows 22% weight loss in early results

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Hosted on MSN · 3d

Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results

KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.The maker of Ozempic and Wegovy said that its Phase 1b/2a trial showed people achieved weight loss from a mean baseline body weight of 92.

Bloomberg on MSN · 3d

Novo Shares Soar as Experimental Shot Shows 22% Weight Loss

Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

2h

Ozempic maker Novo Nordisk failed to disclose more payments made to healthcare groups - watchdog

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...

1d

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results